Foreword: Prevention of COVID-19, Influenza, and Respiratory Syncytial Virus in At-Risk Populations.
作者信息
Gravenstein Stefan
机构信息
Alpert Medical School and Health Services, Policy and Practice, Brown University, Providence, RI, 02903, USA.
出版信息
Infect Dis Ther. 2025 Jan;14(Suppl 1):1-3. doi: 10.1007/s40121-024-01078-y. Epub 2024 Dec 30.
Abstract
摘要
相似文献
1
Foreword: Prevention of COVID-19, Influenza, and Respiratory Syncytial Virus in At-Risk Populations.前言：高危人群中新型冠状病毒肺炎、流感和呼吸道合胞病毒的预防
Infect Dis Ther. 2025 Jan;14(Suppl 1):1-3. doi: 10.1007/s40121-024-01078-y. Epub 2024 Dec 30.
2
A Narrative Review of Key Risk Factors for Severe Illness Following SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Infection.关于新型冠状病毒、流感病毒和呼吸道合胞病毒感染后重症关键危险因素的叙述性综述
Infect Dis Ther. 2025 Jan;14(Suppl 1):39-61. doi: 10.1007/s40121-024-01081-3. Epub 2024 Dec 30.
3
Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative Review.流感病毒、呼吸道合胞病毒和严重急性呼吸综合征冠状病毒2引起的急性呼吸道感染负担：一项纳入老年人的叙述性综述
Infect Dis Ther. 2025 Jan;14(Suppl 1):5-37. doi: 10.1007/s40121-024-01080-4. Epub 2024 Dec 30.
4
Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults.住院美国成年人中呼吸道合胞病毒与 COVID-19 和流感的严重程度比较。
JAMA Netw Open. 2024 Apr 1;7(4):e244954. doi: 10.1001/jamanetworkopen.2024.4954.
5
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.50岁及以上成年人中，mRNA-1345呼吸道合胞病毒疫苗与流感疫苗或新冠疫苗联合接种的安全性和免疫原性：一项观察者盲法、安慰剂对照、随机、3期试验。
Lancet Infect Dis. 2025 Apr;25(4):411-423. doi: 10.1016/S1473-3099(24)00589-9. Epub 2024 Nov 25.
6
Evaluation of Three Multiplex Real-time Reverse Transcription PCR Assays for Simultaneous Detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus in Nasopharyngeal Swabs.评价三种多重实时逆转录聚合酶链反应检测试剂盒在鼻咽拭子标本中同时检测新型冠状病毒、甲型/乙型流感病毒和呼吸道合胞病毒的效果。
J Korean Med Sci. 2021 Dec 13;36(48):e328. doi: 10.3346/jkms.2021.36.e328.
7
The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review.疫苗接种对新冠病毒、流感和呼吸道合胞病毒相关结局的影响：一项叙述性综述
Infect Dis Ther. 2025 Jan;14(Suppl 1):63-97. doi: 10.1007/s40121-024-01079-x. Epub 2024 Dec 30.
8
Influenza A, Influenza B, human respiratory syncytial virus and SARSCoV-2 molecular diagnostics and epidemiology in the post COVID-19 era.后 COVID-19 时代的 A 型流感、B 型流感、人类呼吸道合胞病毒和 SARSCoV-2 的分子诊断和流行病学。
Respir Res. 2024 Jun 5;25(1):234. doi: 10.1186/s12931-024-02862-7.
9
Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents - National Healthcare Safety Network, United States, December 2023.养老院居民中流感、呼吸道合胞病毒和更新的 COVID-19 疫苗的接种情况 - 美国国家医疗保健安全网络，2023 年 12 月。
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1371-1376. doi: 10.15585/mmwr.mm7251a3.
10
Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus.疫苗接种的最佳时机：关于新冠病毒、流感和呼吸道合胞病毒综合策略的叙述性综述
Infect Dis Ther. 2025 May;14(5):911-932. doi: 10.1007/s40121-025-01135-0. Epub 2025 Apr 10.
引用本文的文献
1
Metabolic Reprogramming in Respiratory Viral Infections: A Focus on SARS-CoV-2, Influenza, and Respiratory Syncytial Virus.呼吸道病毒感染中的代谢重编程：聚焦于严重急性呼吸综合征冠状病毒2、流感病毒和呼吸道合胞病毒
Biomolecules. 2025 Jul 16;15(7):1027. doi: 10.3390/biom15071027.
本文引用的文献
1
Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis.社区环境中成年人群体多重疾病的全球和区域患病率：一项系统评价和荟萃分析。
EClinicalMedicine. 2023 Feb 16;57:101860. doi: 10.1016/j.eclinm.2023.101860. eCollection 2023 Mar.
2
Immune Senescence, Immunosenescence and Aging.免疫衰老、免疫细胞衰老与衰老
Front Aging. 2022 May 30;3:900028. doi: 10.3389/fragi.2022.900028. eCollection 2022.
3
Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2.年龄差异与 SARS-CoV-2 合并症负担对不良结局的关联。
BMC Geriatr. 2021 Jul 6;21(1):415. doi: 10.1186/s12877-021-02340-5.
4
Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention.免疫衰老及其特征：如何战略性地对抗衰老？治疗干预潜在选择的综述。
Front Immunol. 2019 Sep 25;10:2247. doi: 10.3389/fimmu.2019.02247. eCollection 2019.
5
The frailty syndrome.衰弱综合征
Clin Med (Lond). 2011 Feb;11(1):72-5. doi: 10.7861/clinmedicine.11-1-72.
Zotero 插件